• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Denali Capital Acquisition Corp. (Amendment)

    2/13/24 4:43:35 PM ET
    $DECA
    Blank Checks
    Finance
    Get the next $DECA alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Denali Capital Acquisition Corp.

    (Name of Issuer)

     

    Class A ordinary share, $0.0001 par value per share

    (Title of Class of Securities)

     

    G6256B106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G6256B106  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Boothbay Fund Management, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0*

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%*

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, OO

     

     

     

     

    CUSIP No. G6256B106  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ari Glass

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0*

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%*

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

     

     

     

    CUSIP No. G6256B106  

     

    Item 1.

     

      (a)

    Name of Issuer

    Denali Capital Acquisition Corp. (the “Issuer”)

         
      (b)

    Address of Issuer’s Principal Executive Offices

    437 Madison Avenue, 27th Floor,

    New York, New York 10022

     

    Item 2.

     

      (a)

    Name of Person Filing:

    Boothbay Fund Management, LLC*

    Ari Glass*

         
      (b)

    Address of the Principal Office or, if none, residence

    140 East 45th Street, 14th Floor

    New York, NY 10017

         
      (c)

    Citizenship

    Boothbay Fund Management, LLC – Delaware

    Ari Glass – United States

         
      (d)

    Title of Class of Securities

    Class A ordinary share

         
      (e)

    CUSIP Number

    G6256B106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) ☐ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) ☐ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) ☒ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) ☐ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) ☒ Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) ☐ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) ☐ Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) ☐ Group, in accordance with §240.13d-1(b)(ii)(K) (a) [_]

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    Boothbay Fund Management, LLC – 0*

    Ari Glass – 0*

         
      (b)

    Percent of class:

    Boothbay Fund Management, LLC – 0%*

    Ari Glass – 0%*

     

     

     

     

    CUSIP No. G6256B106  

     

      (c) Number of shares as to which the person has:
           
        (i)

    Sole power to vote or to direct the vote

    Boothbay Fund Management, LLC – 0

    Ari Glass – 0

           
        (ii)

    Shared power to vote or to direct the vote

    Boothbay Fund Management, LLC – 0*

    Ari Glass – 0*

           
        (iii)

    Sole power to dispose or to direct the disposition of

    Boothbay Fund Management, LLC – 0

    Ari Glass – 0

           
        (iv)

    Shared power to dispose or to direct the disposition of

    Boothbay Fund Management, LLC – 0*

    Ari Glass – 0*

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

     

     

    * The Class A ordinary share, $0.0001 par value (the “Shares”) of the Issuer reported herein are, or were, held by one or more private funds (the “Funds”), which are managed by Boothbay Fund Management, LLC, a Delaware limited liability company (the “Adviser”). Ari Glass is the Managing Member of the Adviser. The Adviser has delegated to certain subadvisors (collectively, “Subadvisors”) the authority to act on behalf of the Funds, including the sole authority to vote and direct the disposition of certain Shares held by the Funds, and such Shares may be, or have been, reported in regulatory filings made by such Subadvisors.

     

    However, this report is being made to the extent that, for the purposes of Reg. Section 240.13d-3, the reporting persons herein are deemed to beneficially own the Shares reported herein, or on previous filings. The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise, that the Adviser, the Funds, Ari Glass or any other person has, or had, beneficial ownership of any securities reported herein and, notwithstanding the inclusion of any security in this report, the Adviser, the Funds, and Ari Glass expressly disclaim beneficial ownership of any security reported herein, or on previous filings, except to the extent of the Adviser’s, the Funds’, or Ari Glass’s pecuniary interest therein (if any), with respect to the Shares which the Adviser has delegated sole investment and voting discretion to a Subadvisor and does not presently have the right to terminate such delegation within sixty days. 

     

     

     

     

    CUSIP No. G6256B106  

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

    Item 10. Certification.

     

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. G6256B106  

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

     

      Boothbay Fund Management, LLC
         
      By: /s/ Ari Glass
        Ari Glass, Managing Member
         
      Ari Glass
         
      By: /s/ Ari Glass
        Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. G6256B106  Exhibit 1

     

    JOINT FILING STATEMENT

    PURSUANT TO RULE 13D-1(K)(1)

     

    The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Class A ordinary shares of Denali Capital Acquisition Corp. together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

     

    Dated: February 13, 2024

     

      Boothbay Fund Management, LLC
         
      By: /s/ Ari Glass
        Ari Glass, Managing Member
         
      Ari Glass
         
      By: /s/ Ari Glass
        Individually

     

     

     

    Get the next $DECA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DECA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DECA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:05:57 AM ET
    $DECA
    Blank Checks
    Finance

    SEC Form 4 filed by Large owner Xu Jiandong

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:01:42 AM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from June 11, 2025 to July 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a busines

    6/11/25 8:30:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

    5/9/25 4:00:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

    4/14/25 4:35:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DECA
    SEC Filings

    View All

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/22/25 5:10:19 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

    S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/21/25 5:17:32 PM ET
    $DECA
    Blank Checks
    Finance

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/15/25 9:20:12 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    12/6/24 4:17:05 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 5:49:50 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 2:35:09 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Financials

    Live finance-specific insights

    View All

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

    As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

    11/6/24 12:24:36 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

    Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

    10/28/24 6:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

    Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

    10/16/24 4:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care